Flag of the European Union EU Clinical Trials Register Help

Clinical trials for II

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    Query did not match any clinical trials.
    These are paediatric studies completed by 26 January 2007, in respect of products authorised in the Community (Article 45 of the Paediatric Regulation (EC) No 1901/2006).
    Note: Advanced search filters for country, trial phase, gender, rare disease, IMP with orphan designation in the indication and age ranges of in-utero, adult or elderly do not apply to these records.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Study title: A clinical trial with Solcoderm, Haim S., Cohen A., 1983, Publication: Solcoderm treatment of epidermal growths including intradermmal nevi, 1984
    Active substance: ACETIC ACID_OXALIC ACID_NITRIC ACID_LACTIC ACID_COPPER (II) NITRATE
    Study summary document link (including results):
    View full study record
    Document reference: 21254
    Study title: Abschlussbericht: Offene kontrollierte Studie zum Vergleich der Wirsamkeit und Verträglichkeit von Solco-Derman und Verrumal bei Hautwarzen, Rozman T, et al., Nov. 7, 1988
    Active substance: ACETIC ACID_OXALIC ACID_NITRIC ACID_LACTIC ACID_COPPER (II) NITRATE
    Study summary document link (including results):
    View full study record
    Document reference: 21256
    Study title: Abschlussbericht: Offene unkontrollierte Studie zur Untersuchung de Wirksamkeit und Verträglichkeit von Solco-Derman bei Hautwarzen, aktinischen Keratosen, Lentigo senilis und Condylomata acuminata, Rozman T et al., January 25, 1989
    Active substance: ACETIC ACID_OXALIC ACID_NITRIC ACID_LACTIC ACID_COPPER (II) NITRATE
    Study summary document link (including results):
    View full study record
    Document reference: 21253
    Study title: Abschlussbericht: Offene unkontrollierte Studie zur Untersuchung de Wirksamkeit und Verträglichkeit von Solco-Derman bei Hautwarzen, aktinischen Keratosen, Lentigo senilis und Condylomata acuminata, Rozman T et al., January 25, 1989
    Active substance: ACETIC ACID_OXALIC ACID_NITRIC ACID_LACTIC ACID_COPPER (II) NITRATE
    Study summary document link (including results):
    View full study record
    Document reference: 21258
    Study title: Abschlussbericht: Offene unkontrollierte Studie zur Untersuchung der Wirksamkeit und Verträglichkeit von Solco-Derman bei Mollusca contagiosa, Rozman T et al., Dec. 13, 1988
    Active substance: ACETIC ACID_OXALIC ACID_NITRIC ACID_LACTIC ACID_COPPER (II) NITRATE
    Study summary document link (including results):
    View full study record
    Document reference: 21257
    Study title: Klinische Dokumentation über die chemochirurgische Alternativbehandlung benigner und maligner Tumoren in der dermatologischen Praxis, Promotionarbeit, Werner Christian Labhardt, 1980
    Active substance: ACETIC ACID_OXALIC ACID_NITRIC ACID_LACTIC ACID_COPPER (II) NITRATE
    Study summary document link (including results):
    View full study record
    Document reference: 21255
    Study title: Offene kontrollierte Studie zum Vergleich der Wirsamkeit und Verträglichkeit von Solco-Derman und Verrumal bei Hautwarzen, Rozman T, et al., Nov. 7, 1988
    Active substance: ACETIC ACID_OXALIC ACID_NITRIC ACID_LACTIC ACID_COPPER (II) NITRATE
    Study summary document link (including results):
    View full study record
    Document reference: 21250
    Study title: Offene unkontrollierte Studie zur Untersuchung der Wirksamkeit und Verträglichkeit von Solco-Derman bei Mollusca contagiosa, Rozman T et al., Dec. 13, 1988
    Active substance: ACETIC ACID_OXALIC ACID_NITRIC ACID_LACTIC ACID_COPPER (II) NITRATE
    Study summary document link (including results):
    View full study record
    Document reference: 21252
    Study title: Report on a controlled study with "Solcoderm", Avraham A., 1980
    Active substance: ACETIC ACID_OXALIC ACID_NITRIC ACID_LACTIC ACID_COPPER (II) NITRATE
    Study summary document link (including results):
    View full study record
    Document reference: 21251
    Study title: Solcoderm study 006-I1: A double blind clinical comparison of Solcoderm with plain nitric acid of similar acid strnght." M. Weiner, Cincinatti, 1981, Solco-Study A clinical trial with Solcoderm, Authors: Haim S., Cohen A., Dec 1979, Israeli Study (summary)
    Active substance: ACETIC ACID_OXALIC ACID_NITRIC ACID_LACTIC ACID_COPPER (II) NITRATE
    Study summary document link (including results):
    View full study record
    Document reference: 21248
    Study title: Solcoderm study 006-I2: "A double-blind evaluation of Solcoderm variants using pairs of comparable skin tumors."
    Active substance: ACETIC ACID_OXALIC ACID_NITRIC ACID_LACTIC ACID_COPPER (II) NITRATE
    Study summary document link (including results):
    View full study record
    Document reference: 21249
    Study title: A MULTI-CENTER, INVESTIGATOR-MASKED, RANDOMIZED, ACTIVE CONTROLLED, PARALELL GROUP SUPERIORITY STUDY TO COMPARE THE CLINICAL EFFICACY OF ADAPALENE GEL, 0.3% VERSUS ADAPALENE GEL, 0.1%, IN THE TREATMENT OF ACNE VULGARIS - PHASE III
    Active substance: ADAPALENE
    Study summary document link (including results):
    View full study record
    Document reference: 46279
    Study title: A MULTICENTER, RANDOMIZED, INVESTIGATOR-BLINDED, PARALLEL GROUP COMPARISON OF ADAPALENE GEL (CD271G) 0.1% AND ITS VEHICLE IN THE TREATMENT OF ACNE VULGARIS - PHASE III
    Active substance: ADAPALENE
    Study summary document link (including results):
    View full study record
    Document reference: 46290
    Study title: A PILOT STUDY OF EFFICACY AND TOLERANCE OF ADAPALENE 0.1% GEL AND ITS VEHICLE IN THE TREATMENT OF ACNE SCARS : A SINGLE BLIND PARALLEL GROUP STUDY OF 48-WEEK TOPICAL APPLICATION - PHASE IIA
    Active substance: ADAPALENE
    Study summary document link (including results):
    View full study record
    Document reference: 46265
    Study title: US - BILATERAL FACIAL TOLERANCE COMPARISON OF DIFFERIN TM (ADAPALENE GEL) GEL, 0.1% POST WASHING – CLINICAL PHASE II
    Active substance: ADAPALENE
    Study summary document link (including results):
    View full study record
    Document reference: 46254
    Study title: US - EFFICACY AND SAFETY OF ADAPALENE GEL, 0.3% COMPARED TO TAZAROTENE GEL, 0.1% IN THE TREATMENT OF ACNE VULGARIS - PHASE IIIB
    Active substance: ADAPALENE
    Study summary document link (including results):
    View full study record
    Document reference: 46283
    Study title: US - EVALUATION OF DIFFERIN GEL 0,1% vs. VEHICULE ON FACIAL ACNE SUBJECTS WHO SUCCESSFULLY RESPONDED TO A FIRST COURSE THERAPY WITH ORAL ISOTRETINOIN - PHASE III
    Active substance: ADAPALENE
    Study summary document link (including results):
    View full study record
    Document reference: 46275
    Study title: AU: De-Falco-F-A, D-Angelo-E, Grimaldi-G, Scafuro-F, Sachez-F, Caruso-G. IN: Cattedra di Neurofisiopatologia, II Facolta di Medicina e Chirurgia, Universita degli Studi di Napoli. TI: Effect of the chronic treatment with L-acetylcarnitine in Down's syndrome SO: La Clinica terapeutica {Clin-Ter} 1994 Feb, VOL: 144 (2), P: 123-7,.
    Active substance: ACETYL-L-CARNITINE
    Study summary document link (including results):
    View full study record
    Document reference: 46203
    Study title: Phase II single-centre, randomised, open study comparing 20 treated patients versus 20 historical non treated patients with Rett Syndrome (RS)
    Active substance: ACETYL-L-CARNITINE
    Study summary document link (including results): ST200 DS 2001 002 linelisting2011.xls
    View full study record
    Document reference: 46200
    Study title: Titolo protocollo: SAFETY AND EFFICACY OF ACETYL-L-CARNITINE SUPPLEMENTATION IN PEDIATRIC PATIENTS WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER: A PHASE II, DOSE RANGING TRIAL
    Active substance: ACETYL-L-CARNITINE
    Study summary document link (including results): ST 01 101 linelisting2011.xls
    View full study record
    Document reference: 46206
    1  2  3  4  5  6  7  8  9  Next» Last»»
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jul 05 12:42:27 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA